Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis - Wikidata - wikimedia - TriplyDB

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

http://www.wikidata.org/entity/Q37247606

about

Mucormycosis, pseudallescheriasis, and other uncommon mold infections The spectrum of fungi that infects humans Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.Recent advances in the treatment of mucormycosis.Human Fungal Pathogens of Mucorales and Entomophthorales.Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.Targeting iron assimilation to develop new antibacterials.Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Iron overload and allogeneic hematopoietic stem-cell transplantation.Immunotherapy against invasive mold infections.Update on mucormycosis pathogenesis.Host-iron assimilation: pathogenesis and novel therapies of mucormycosis.Risk factors for mortality in patients with mucormycosis Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Molecular mechanisms of mucormycosis-The bitter and the sweet.Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.Iron starvation induces apoptosis in Rhizopus oryzae in vitro.Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient - the need for prompt treatment.Mucormycosis: a rare fungal infection in tornado victims.Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series

P2860

Q24603297-2C52F1B0-B55B-41D6-9CA1-4275114743A9 Q28652321-86AD4D0E-90A1-4CCB-BF2D-6F1E8C0C0501 Q30873926-231F659A-10F1-4758-9E13-55FBB9774CA3 Q33644747-0C541AF8-E021-4355-BD8A-F60C2905E6F4 Q34161213-1BACE5EF-723B-49D0-A973-A1C963DBAF57 Q35245238-DFD878A9-EA51-46B4-88F4-15EF83991B26 Q35364288-3732A458-08A8-4369-8629-4D48024D3351 Q36058200-F528D38E-4E04-4723-AE56-00E4BF62AB0A Q36211648-B1A5A48F-B7D2-4383-A16E-9A0C2CA76F8B Q36862446-AD6EF382-CFE1-4118-8F4C-F110F780365F Q36951755-1C1328A7-EC5D-45C9-9288-17F7784135E0 Q37439356-01785B03-0D37-4F57-B5D7-DF2C00B0276E Q37816399-34C3FE07-51E6-4F8F-8AFF-6CD56CC78A18 Q37842351-49A9FC38-490D-4B44-B755-8A544EF8E01A Q37965757-AB31F22C-4F09-4E94-BCF8-DEF292671607 Q38152678-E39471F7-BB77-4DD1-8407-C2BD78BDE88D Q38245340-2C02C57D-2928-429F-A5E4-04928A340ECF Q38261678-D860A745-EBC2-487D-8E2E-3AE7E832DFD2 Q38284463-05E093AC-8612-4A03-BF84-4F9307566897 Q40108307-E23E79D4-1782-41EC-B50C-50524968B14D Q40617936-9499C465-CEED-4693-9025-D4A87B457273 Q41364249-8E3EAADC-26FD-4956-A0C6-254E9CF291CB Q41443344-E3E0B78C-9F63-4111-9DF6-C1B55411E328 Q41968745-CA4B0381-5DAA-43B4-9AF4-058EB70DB9FF Q42706346-A02C3FD1-A9B9-4843-B9F8-B8EF417E232D Q43044189-DCD0A015-A3CA-428C-BDEA-BF475A21B747 Q43199274-C1C00DAB-3AF9-4F09-AC69-790529353F5D Q57821495-32FADA66-6D54-4095-A2BA-29C95662CAAB

P2860

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

http://www.wikidata.org/entity/Q37247606

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

@en

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

@nl

type

label

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

@en

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

@nl

prefLabel

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

@en

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

@nl

P1433

Q37247606-E963D29C-CD28-4545-BE64-47C634B47014

P1476

Q37247606-2A784CFC-7FF3-4829-BC16-56BB19002547

P2093

Q37247606-74E8C31B-E47F-4EAB-B4C0-A2C5404F5040

Q37247606-8D8E8C1D-0812-4B70-8C5A-E0BE91CBA9EC

Q37247606-9EA254CB-7B41-42FB-BF27-422C1CB4244D

Q37247606-AAD34F47-5198-43BE-9F4A-A5A3A9CE1210

Q37247606-B0298046-96AE-431A-9CA0-3CDCB3522F2B

Q37247606-CA0DB2C8-1D56-47F8-B448-1C92D5C129CA

Q37247606-D2AB5FFD-7B6F-4A7A-A0DB-E2048E532AFF

P2860

Q37247606-156CF5C3-F472-48D4-92D6-EE76EA06CCC2

Q37247606-15727DEB-2FEB-4D43-B481-30661AABC46D

Q37247606-35549275-1D8B-49A1-92F5-D0E3657725FB

Q37247606-44F913B9-C643-49FB-9373-FAF47E41F3FC

Q37247606-499D3B5A-09D5-4B4B-B82B-2E0BC25E1962

Q37247606-6220EF89-EDC7-4335-925F-383FCB767E43

Q37247606-7216E5A1-2E61-499C-B5F6-B0DA7F739519

Q37247606-9FF23B46-296C-4110-B760-7D950A05D466

Q37247606-A79A2A12-B6BD-4921-A003-816E90BABC62

Q37247606-AC6C5E2C-8C9F-40FE-BCDB-3AC7161DF492

P304

Q37247606-61A0804B-D542-4C54-A6B8-A516B38296E8

P31

Q37247606-99007231-9F83-4CFE-8C88-7AF507212A4B

P356

Q37247606-5F306B4B-9D3C-4260-82BA-4527A5C9268D

P407

Q37247606-9FE9968A-DF0C-4EAA-B0E9-2805B36B5D0E

P433

Q37247606-6274065B-25DB-4CDE-AACE-3B4DCB8CAF4F

P478

Q37247606-86855F53-8045-4329-BE27-54FC6AB384FA

P50

Q37247606-0C56BDF5-C9E1-4C8B-AEAE-D42A2BBA80A2

P577

Q37247606-A28D5884-9D73-49E2-99BD-D16357837F5E

P698

Q37247606-A2813252-0D83-434C-9F38-07BA70316DA6

P921

Q37247606-846b4a39-9021-41cf-90c2-b8811d108b40

P932

Q37247606-4C5BBC30-FDE0-44FC-A6B2-CB5E5F86DC12

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

@en

P2093

Anne Anglim

http://www.w3.org/2001/XMLSchema#string

Ashraf S Ibrahim

http://www.w3.org/2001/XMLSchema#string

Brad Spellberg

http://www.w3.org/2001/XMLSchema#string

Glenn E Mathisen

http://www.w3.org/2001/XMLSchema#string

Hector Bonilla

http://www.w3.org/2001/XMLSchema#string

Mario Perez

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

P2860

Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

A higher-level phylogenetic classification of the Fungi

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Epidemiology and outcome of zygomycosis: a review of 929 reported cases.

The iron chelator deferasirox protects mice from mucormycosis through iron starvation

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

Clinical application of deferasirox: practical patient management.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.

Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

P304

3122-3125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00361-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19433555

http://www.w3.org/2001/XMLSchema#string

P921

chelation therapy

P932

2704638

http://www.w3.org/2001/XMLSchema#string